News

Markers of Inflammation Correlate With Longitudinal Cognitive Decline in People With Mild Cognitive Impairment

Markers of Inflammation Correlate With Longitudinal Cognitive Decline in People With Mild Cognitive Impairment At 9 and 15 months of follow up, higher cerebrospinal fluid (CSF) levels of the inflammatory marker monocyte chemoattractive protein-1 (CCL2) and lower levels of the anti-inflammatory molecule plasma α1-antitrypsin both correlated with greater cognitive declines in people with mild cognitive impairment. Plasma α1-antitrypsin is an acute phase reactant with anti-inflammatory, anti- leukocyte migratory activity and CCL2 is a key regulator of monocyte and macrophage...

Read More

Pimavanserin Reduce Risks of Dementia-Related Psychotic Relapse Almost Threefold

In top-line results from the pivotal phase 3 HARMONY (NCT03325556) study, treatment with pimavanserin vs placebo (Nuplazid, Acadia Pharmaceuticals, San Diego, CA) reduced risk of psychotic relapse by 2.8 fold (HR = 0.353; one-sided P = .0023) for people with dementia-related psychosis (DRP). People treated with pimavanserin were 2.2 times less likely to discontinue the study medication compared with those treated with placebo (HR = 0.452; one-sided P= .0024). This finding met the predetermined primary endpoint; as a result, the study was terminated early for efficacy. In an initial...

Read More

Oculomotor Test for Parkinson’s Disease Receives Breakthrough Device Designation

The Food and Drug Administration (FDA) breakthrough device program was designed to streamline the market clearance and approval process for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Oculomotor Test System (RightEye, Bethesda, MD) has received the first and only breakthrough device designation for a device that uses objective eye movement measurements to aid in the assessment of Parkinson's disease (PD). Research has demonstrated that individuals with PD exhibit persistent...

Read More

Latest News Articles

12.05.19

Markers of Inflammation Correlate With Longitudinal Cognitive Decline in People With Mild Cognitive Impairment

KEYWORDS:
Dementia
Neuroinflammation

Markers of Inflammation Correlate With Longitudinal Cognitive Decline in People With Mild Cognitive Impairment At 9 and 15 months of follow up, higher...

Alzheimer's & Dementia

12.04.19

Pimavanserin Reduce Risks of Dementia-Related Psychotic Relapse Almost Threefold

KEYWORDS:
Alzheimer Disease
Dementia
Frontotemporal dementia
Lewy body dementia
Parkinson disease
Parkinson disease psychosis
Vascular dementia

In top-line results from the pivotal phase 3 HARMONY (NCT03325556) study, treatment with pimavanserin vs placebo (Nuplazid, Acadia Pharmaceuticals, San Diego,...

Alzheimer's & Dementia Movement Disorders

12.04.19

Oculomotor Test for Parkinson’s Disease Receives Breakthrough Device Designation

KEYWORDS:
Parkinson disease
Tremor

The Food and Drug Administration (FDA) breakthrough device program was designed to streamline the market clearance and approval process for certain medical...

Imaging & Testing Movement Disorders

12.03.19

Fenfluramine Results in 54% Reduction in Mean Monthly Convulsive Seizure Frequency

KEYWORDS:
Dravet syndrome
Epilepsy
Fenfluramine
Seizures
Stiripentol

JAMA Neurology has published the results of study 1504 phase 3 study (NCT02926898) of the investigational drug, fenfluramine (ZX008, Fintepla), in participants...

Epilepsy & Seizures

12.03.19

Edaravone Oral Formulation Being Tested in Phase 3 Trial for ALS

KEYWORDS:
Amyotrophic Lateral Sclerosis
Edaravone
Phase 3 clinical trial

The first participant has been enrolled in a global phase 3 study (NCT04165824) of an oral suspension formulation of edaravone (Radicava; Mitsubishi Tanabe...

Neuromuscular

12.02.19

FDA Accepts Investigational New Drug Application for SKL24741 for Potential Treatment of Epilepsy

KEYWORDS:
Epilepsy
Seizures

The US Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for SKL24741 (SK LIfe Sciences, Parmus, NJ), for the...

Epilepsy & Seizures

12.02.19

Satralizumab, a Subcutaneously Delivered Monoclonal Antibody, Reduces NMOSD Relapses Over 144-Week Period

KEYWORDS:
Neuromyelitis optica spectrum disorders
Satralizumab

The Food and Drug Administration (FDA) accepted a biologics license application (BLA) for satralizumab (Genentech, San Francisco, CA) for the treatment of...

MS & Immune Disorders

11.26.19

Pharmacokinetic Study Suggests Hydromethylthionine May Have Dose-Dependent Effect on Alzheimer’s Disease

KEYWORDS:
Alzheimer Disease
Dementia
Early onset Alzheimer disease
Hydromethylthionine

A new pharmacokinetic population analysis of hydromethylthionine (TauRx, Aberdeen, Scotland) has been published in the Journal of Alzheimer's Disease. The...

Alzheimer's & Dementia

11.26.19

Midazolam Nasal Spray for Acute Treatment of Seizure Clusters To Be Available In December

KEYWORDS:
Acute repetitive seizures
Cluster seizures
Epilepsy
Midazolam
Seizures

In December, midazolam nasal spray (Nayzilam; UCB, Atlanta, GA) will be available in retail pharmacies for acute treatment of intermittent, stereotypic seizure...

Epilepsy & Seizures

11.25.19

Risdiplam for Spinal Muscular Atrophy New Drug Application Accepted

KEYWORDS:
Child neurology
Neuromuscular disease
Risdiplam
Spinal muscular atrophy

The FDA has accepted new drug application (NDA) and granted priority review for risdiplam (Genentech, San Francisco, CA), an investigational, survival...

Child Neurology Neuromuscular

11.22.19

FDA Approves Cenobamate for Treatment of Partial-Onset Seizures in Adults

KEYWORDS:
Cenobamate
Epilepsy
FDA Approvals
Seizures

The Food and Drug Administration has approved cenobamate (Xcopri; SK Life Sciences, Paramus, NJ) for the treatment of partial-onset seizures in...

Epilepsy & Seizures

11.20.19

Freedom from Pain and Most Bothersome Symptoms of Migraine With Ubrogepant in Phase 3 Trial

KEYWORDS:
Headache
Migraine
Ubrogepant

Positive results were achieved in the phase 3 clinical trial that evaluated ubrogepant (Allergan; Dublin, Ireland) for acute treatment of migraine. The data is...

Headache & Pain

11.20.19

Advancement in Multiple Sclerosis and The Effect on Pregnancy

KEYWORDS:
Multiple sclerosis
Pregnancy

On a global level, there is a concerning gap between the results of clinical trials and regulators' approval of advanced therapies, leaving some individuals...

MS & Immune Disorders

11.19.19

Stem-Cell Derived Astrocytes for Amyotrophic Lateral Sclerosis: Positive Interim Results May Lead to Amending Phase 1/2a Protocol

KEYWORDS:
Amyotrophic Lateral Sclerosis
Stem-cell treatment

An amendment will be submitted for an ongoing phase 1/2a clinical trial protocol of an “off-the-shelf" clinical-grade cell product (AstroRX;...

Neuromuscular

11.19.19

A New Tau Aggregation Inhibitor Arrives on the Scene

KEYWORDS:
Alzheimer Disease
Frontotemporal dementia
Parkinson disease
Tauopathies

As published today in the Journal of Alzheimer’s Disease, a new oral small molecule drug (Oligomerix, Bronx, NY) has been shown, in the htau mouse, to...

Alzheimer's & Dementia Movement Disorders

11.15.19

Cenobamate Reduces Seizure Frequency Significantly in Phase 2 Trial

KEYWORDS:
Cenobamate
Epilepsy
Seizures

In the phase 2 trial (NCT01866111) treatment with cenobamate (SK Life Science, Paramus, NJ) resulted in statistically significant greater reductions in focal...

Epilepsy & Seizures

11.13.19

Neflamapimod Granted Fast Track Status by FDA

KEYWORDS:
Alzheimer Disease
Dementia
Parkinson disease

The Food and Drug Administration (FDA) has granted fast track designation to neflamapimod (EIP Pharma Inc, Boston, MA) as a potential treatment for dementia...

Alzheimer's & Dementia Movement Disorders

11.13.19

Remote Electric Neuromodulation As Effective as Pharmacologic Therapies for Migraine

KEYWORDS:
Headache
Migraine
Neuromodulation
Remote electrical neuromodulation

An article published in Headache describes the promise of remote electric neuromodulation (REN) as an alternative to current therapies and a...

Headache & Pain

11.12.19

Risdiplam Improves Motor Function in Spinal Muscular Atrophy

KEYWORDS:
Antisense oligonucleotide therapy
Risdiplam
Spinal muscular atrophy

The SUNFISH (NCT02908685) pivotal part 2 study showed improved motor function after treatment with risdiplam for people with spinal muscular atrophy...

Child Neurology Neuromuscular

11.12.19

Gold Nanoparticle Treatment Being Tested for Treatment of Amyotrophic Lateral Sclerosis, Parkinson’s Disease, and Multiple Sclerosis

KEYWORDS:
Amyotrophic Lateral Sclerosis
Gold nanocrystal
Multiple sclerosis
Parkinson disease

A proprietary and investigational agent consisting of pure clean-surfaced faceted gold nanocrystals suspended in buffered pharmaceutical grade water (CNM-Au8;...

Movement Disorders MS & Immune Disorders Neuromuscular

Show More

This Month's Issue

RAPID Automated CT Perfusion in Clinical Practice

Brady Laughlin, DO; Alex Chan, DO; Waimei Amy Tai, MD; and Parham Moftakhar, MD

Headache Horizons: Migraine Auras

Daniel McNavish

The Importance of Neuroimaging

Anand Karthik Sarma, MD

November/December 2019 cover

Full Issue

Case Reports